IBG vs RKDA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IBG exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 3/9 and a catastrophic price collapse of over 93% in the last year. While the company maintains a strong gross margin of 76.14%, this is completely offset by an operating margin of -121.97% and an ROE of -159.34%. The extremely low Price-to-Book ratio (0.17) suggests a value trap rather than a bargain, as the company's liquidity is precarious with a Quick Ratio of only 0.28. Overall, the deterministic indicators and price action signal a high risk of insolvency or further dilution.
RKDA exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all health metrics. Despite a strong current ratio of 3.09 suggesting short-term liquidity, the company suffers from severe operational inefficiency with an operating margin of -152.61% and declining year-over-year revenue growth of -25.90%. The catastrophic 5-year price decline of -98.8% and a 0/100 technical trend score confirm a persistent bearish trajectory. The stock is currently a classic value trap, trading at a low Price/Book (0.39) but lacking any catalyst for recovery.
Compare Another Pair
Related Comparisons
IBG vs RKDA: Head-to-Head Comparison
This page compares Innovation Beverage Group Limited (IBG) and Arcadia Biosciences, Inc. (RKDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.